

ZOGENIX

Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6

February 27, 2018

EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, March 6, 2018, at 4:30 PM Eastern Time.

Conference Call Details

Tuesday, March 6th @ 4:30 PM Eastern Time/1:30 PM Pacific Time

Toll Free: 800-239-9838
International: 323-794-2551
Conference ID: 5092266
Webcast: <http://public.viavid.com/index.php?id=128365>

Replays, available through March 20:

Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 5092266

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

CONTACT:

Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Zogenix

Source: Zogenix, Inc.